Markets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...

Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...

India's corporate earnings for the quarter ended March 2026 are feeling the economic heat from the recent Israel-US-Iran conflict. While so...

Expert CA Rudramurthy BV suggests a bullish stance. He recommends buying on dips, especially in pharma stocks like Glenmark, Laurus Labs, a...

Biocon shares: The decision comes after receiving approvals from the Board of Directors in April and from shareholders through a postal bal...

Biocon shares: The board approved a hike in the company’s authorised share capital from Rs 625 crore to Rs 700 crore, along with a correspo...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...

Biocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...

Biocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...

Biocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...

Biocon Ltd., incorporated in the year 1978, is a Large-Cap company (with a market cap of Rs 43209.59 Crore) operating in Pharmaceuticals se...

Biocon posted a net profit of Rs 130 crore for the quarter ended March 31, 2018. The company had recorded a net profit of Rs 127 crore for ...

At the end of 2015, 70% of analysts tracking the Biocon stock had a buy recommendation on it. Data from Bloomberg show that this number has...

While most pharma companies have turned risky on account of regulatory clamps, investors have switched to companies with healthy pipeline a...

Contributing one-fourth of the consolidated revenues, Syngene has been Biocon's best-performing segment in the last couple of years.

Investors must adopt stock-specific approach as valuations have turned expensive on pharma counters, says Joshi in an interview to ET Now.

Over the last few days, the developments have been quite positive in Biocon.